Department of Radiology and Radiological Science, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC 29425, USA.
AJNR Am J Neuroradiol. 2010 Jun;31(6):1151-6. doi: 10.3174/ajnr.A1974. Epub 2010 Jan 6.
Spinal MRA has been increasingly used to evaluate non-invasively the spinal cord vasculature. Our aim was to prospectively compare gadobenate dimeglumine with gadodiamide in the assessment of the normal spinal cord vasculature by using contrast-enhanced MRA, with the hypothesis that high T1 relaxivity gadolinium compounds may improve visualization of the intradural vessels.
Twenty subjects underwent 2 temporally separated contrast-enhanced spinal MRAs with gadobenate dimeglumine and gadodiamide (0.2 mmol/kg). Two blinded observers rated postprocessed images on the following qualitative parameters: background homogeneity, sharpness, vascular continuity, and contrast enhancement. Delineation of the ASA, AKA, hairpin configuration of the ASA-AKA connection, and visualized ASA length were recorded. Each observer indicated which of the 2 matched studies he or she thought was of the best overall diagnostic quality.
According to both observers gadobenate dimeglumine was superior to gadodiamide in the representation of vascular continuity and contrast (P value < .05). Background homogeneity was not significantly different between the studies. One observer favored gadobenate dimeglumine over gadodiamide in the demonstration of vascular sharpness, while the second observer did not find any significant difference between contrast agents. There was no significant difference between contrast agents in the visualization of the ASA, AKA, hairpin-shaped ASA-AKA connection, and visualized length of the ASA. The overall quality of the gadobenate dimeglumine-enhanced MRA was deemed superior in 15 and 16 cases, respectively, by the 2 observers.
Improved image quality and vascular contrast enhancement of spinal MRA at 1.5T is achieved with high T1 relaxivity gadolinium contrast agents compared with conventional agents at equivalent doses.
脊髓 MRA 已越来越多地用于非侵入性评估脊髓血管。我们的目的是前瞻性比较钆贝葡胺和钆喷酸葡胺在评估正常脊髓血管的对比增强 MRA 中的作用,假设高 T1 弛豫率的钆对比剂可能会改善硬膜内血管的可视化。
20 名受试者先后接受了两次钆贝葡胺和钆喷酸葡胺(0.2mmol/kg)的时间分离的对比增强脊髓 MRA。两名盲法观察者根据以下定性参数对后处理图像进行评分:背景均匀性、清晰度、血管连续性和对比增强。记录 ASA、AKA 的轮廓、ASA-AKA 连接的发夹状结构和可视化的 ASA 长度。每位观察者指出他或她认为哪项研究的整体诊断质量最好。
根据两位观察者的意见,在血管连续性和对比度方面,钆贝葡胺均优于钆喷酸葡胺(P 值<.05)。两种研究之间的背景均匀性无显著差异。一位观察者认为在显示血管清晰度方面,钆贝葡胺优于钆喷酸葡胺,而第二位观察者则认为两种对比剂之间无显著差异。在可视化 ASA、AKA、发夹状 ASA-AKA 连接和可视化 ASA 长度方面,两种对比剂之间无显著差异。在 15 例和 16 例中,两位观察者均认为钆贝葡胺增强的 MRA 整体质量更优。
在 1.5T 时,与常规对比剂相比,高 T1 弛豫率的钆对比剂可提高脊髓 MRA 的图像质量和血管对比度增强。